瑞格列奈与阿卡波糖治疗老年2型糖尿病疗效的对比观察

目的通过动态血糖检测（CGMS）比较瑞格列奈和阿卡波糖治疗老年2型糖尿病的疗效。方法选择2012年1月—2014年3月本院收治的80例老年2型糖尿病患者（年龄在60岁以上）为研究对象,随机分为观察1组和观察2组,各40例,两组患者均给予饮食和运动疗法,观察1组患者给予瑞格列奈治疗,观察2组患者给予阿卡波糖治疗,持续治疗4周,比较两组患者治疗前后CGMS检测数据,包括空腹血糖、餐后2h血糖、肝功能指标等。结果观察1组治疗后空腹血糖、餐后2h血糖以及肝功能指标低于观察2组,差异有统计学意义（P〈0.05）;观察1组不良反应发生率低于观察2组,差异有统计学意义（P〈0.05）。结论瑞格列奈对老年2型糖尿病患者的降糖作用明显优于阿卡波糖,且24h血糖波动幅度较小。

Clinical Effect between Rrepaglinide and Acarbose in the Treatment of Elderly Patients with Type 2 Diabetes:A Com-parison

Objective To compare the clinical effect between repaglinide and acarbose in the treatment of elderly patients with type 2 diabetes, evaluated by continuous glucose monitoring system （CGMS）. Methods A tota of 80 elderly patients with type 2 diabetes in our hospital from January 2012 to March 2014 were randomly divided into the observation group 1 and observation group 2, 40 cases in each. Both groups were treated with diet and exercise therapy. The observation group i was treated with repaglinide, while observation group 2 was treated with acarbose, the treatment lasted for 4 weeks. The CGMS test data, including fasting blood glucose, postprandial 2h blood glucose, liver function index of two groups were compared. Results After treatment, fasting blood glucose, postprandial 2h plasma glucose and liver function index of observation group 1 were lower than those of observation group 2, the differences were statistically significant （ P 〈 0. 05 ）. Incidence of adverse reactions of observation group 1 was lower than that of observation group 2, the difference was statistically significant （ P 〈 0.05 ）. Conclusion Repaglinide has better clinical effect in the treatment of elderly patients with type 2 diabetes than acarbose, and 24h blood sugar fluctuations is less.